The effect of the cardiotonic imazodan (CI-914) on myocardial and peripheral hemodynamics in the anesthetized dog.
The purpose of this study was to evaluate the effect of the new cardiotonic, imazodan (CI-914), on myocardial hemodynamics and oxygen consumption, and peripheral blood flow distribution. Organ blood flow was measured by the radiolabeled-microsphere-reference-withdrawal technique and myocardial oxygen consumption calculated from arterial and coronary sinus O2 content and blood flow. At inotropic levels, CI-914 decreases mean arterial pressure with a minimal increase in heart rate. CI-914 decreases coronary vascular resistance and increases supply to demand ratio, indicating an active coronary vasodilation. CI-914 does not alter peripheral blood flow distribution, thus suggesting equivalent organ vasodilation. These data suggest that CI-914 may be useful in the treatment of congestive heart failure because of its positive inotropic, coronary vasodilator, and peripheral vasodilator properties.
D000631:Aminopyridines / Q000494:pharmacology; D000676:Amrinone; D000818:Animals; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004285:Dogs; D005260:Female; D006321:Heart / Q000187:drug effects*; D006439:Hemodynamics / Q000187:drug effects*; D008297:Male; D009206:Myocardium / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects*; D011724:Pyridazines / Q000494:pharmacology*; D012039:Regional Blood Flow / Q000187:drug effects
D000631:Aminopyridines; D002316:Cardiotonic Agents; D011724:Pyridazines; C042527:imazodan; D000676:Amrinone